Phase III trials are large-scale studies that compare the new treatment to the current standard of care, with an emphasis on confirming effectiveness and long-term safety. 

Endpoints in this phase prioritize overall survival (OS), progression-free survival (PFS), and quality of life (QoL) to assess whether the treatment offers meaningful benefits over existing options. These trials often provide the critical evidence needed for regulatory approval, as they demonstrate the treatment’s impact on both the length and quality of life for multiple myeloma patients.